Effect of the oral antibilharzial niridazole (ambilhar) on patients with concomitant schistosomiasis and HBs antigenaemia.
Twenty-three patients received oral antibilharzial therapy in the form of niridazole tablets (10 mg/kg body weight for 20 days), and 10 patients served as controls. Three months post-therapy, 14 out of 23 treated patients (61%) had cleared the HBsAg. This was found to be statistically significant. In contrast, 2 of the controls (20%) had eliminated the HBsAg from the serum. It is concluded that patients suffering from concomitant schistosomiasis and HBs antigenaemia are enabled to eliminate the HBsAg after niridazole therapy.
D000328:Adult; D006514:Hepatitis B Surface Antigens / Q000032:analysis*; D006801:Humans; D007111:Immunity, Cellular; D008297:Male; D009560:Niridazole / Q000627:therapeutic use*; D012552:Schistosomiasis / Q000188:drug therapy* / Q000276:immunology
D006514:Hepatitis B Surface Antigens; D009560:Niridazole